Preventive and/or therapeutic agent for neutrophilic inflammatory diseases
View Patent ↗The present invention provides a preventive and/or therapeutic agent for neutrophilic inflammatory diseases which comprises, as an active ingredient, a bicyclic heterocyclic compound represented by formula (I): [wherein R 1 represents a hydrogen atom, substituted or unsubstituted alkyl, or the like, A 1 -A 2 -A 3 -A 4 represents N═CR 3 —CR 4 ═CR 5 (wherein R 3 , R 4 , and R 5 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, and the like), Q represents substituted or unsubstituted phenylene, and the like, and T represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aroyl, and the like].
1. A bicyclic heterocyclic compound represented by formula (IIIa):
[wherein R 11e represents substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aliphatic heterocyclic group, substituted or unsubstituted lower cycloalkylcarbonyl, —C(═O)NHR 15d (wherein R 15d represents substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl), or —S(O) 2 R 17a (wherein R 17a represents substituted or unsubstituted aryl) and
R 35a , R 36a , and R 37a are the same or different and each represents a hydrogen atom, or substituted or unsubstituted lower alkyl] or a pharmaceutically acceptable salt thereof.
2. The bicyclic heterocyclic compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 11e is substituted or unsubstituted lower cycloalkyl.
3. The bicyclic heterocyclic compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 11e is a substituted or unsubstituted aliphatic heterocyclic group.
4. The bicyclic heterocyclic compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 11e is substituted or unsubstituted cyclohexyl.
5. The bicyclic heterocyclic compound or the pharmaceutically acceptable salt thereof according to claim 4 , wherein R 35a , R 36a , and R 37a are the same or different and each is lower alkyl.
6. The bicyclic heterocyclic compound or the pharmaceutically acceptable salt thereof according to claim 4 , wherein R 35a , R 36a , and R 37a are methyl.
7. The bicyclic heterocyclic compound or the pharmaceutically acceptable salt thereof according to claim 3 , wherein R 35a , R 36a , and R 37a are the same or different and each is lower alkyl.
8. The bicyclic heterocyclic compound or the pharmaceutically acceptable salt thereof according to claim 3 , wherein R 35a , R 36a , and R 37a are methyl.
9. The bicyclic heterocyclic compound or the pharmaceutically acceptable salt thereof according to claim 2 , wherein R 35a , R 36a , and R 37a are the same or different and each is lower alkyl.
10. The bicyclic heterocyclic compound or the pharmaceutically acceptable salt thereof according to claim 2 , wherein R 35a , R 36a , and R 37a are methyl.
11. The bicyclic heterocyclic compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 35a , R 36a , and R 37a are the same or different and each is lower alkyl.
12. The bicyclic heterocyclic compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 35a , R 36a , and R 37a are methyl.
13. A bicyclic heterocyclic compound represented by formula (IIIb):
(wherein X 3 and X 4 represent hydrogen atoms or X 3 and X 4 are combined together to represent an oxygen atom, R 45a and R 45b are the same or different and each represents a hydrogen atom or substituted or unsubstituted lower alkyl, or R 45a and R 45b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted aliphatic heterocyclic group, and
R 35a , R 36a , and R 37a are the same or different and each represents lower alkyl) or a pharmaceutically acceptable salt thereof.
14. The bicyclic heterocyclic compound or the pharmaceutically acceptable salt thereof according to claim 13 , wherein X 3 and X 4 are combined together to represent an oxygen atom.
15. The bicyclic heterocyclic compound or the pharmaceutically acceptable salt thereof according to claim 13 , wherein X 3 and X 4 are hydrogen atoms.
16. The bicyclic heterocyclic compound or the pharmaceutically acceptable salt thereof according to claim 13 , wherein R 45a is a hydrogen atom and R 45b is substituted or unsubstituted lower alkyl.
17. The bicyclic heterocyclic compound or the pharmaceutically acceptable salt thereof according to claim 13 , wherein R 45a is a hydrogen atom and R 45b is lower alkyl substituted by aliphatic heterocyclic group.
18. The bicyclic heterocyclic compound or the pharmaceutically acceptable salt thereof according to claim 13 , wherein R 45a is a hydrogen atom and R 45b is ethyl substituted by aliphatic heterocyclic group.
19. The bicyclic heterocyclic compound or the pharmaceutically acceptable salt thereof according to claim 13 , wherein R 45a and R 45b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted aliphatic heterocyclic group.